Endurance (Cayman) Ltd Svf Sells 50,173 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) major shareholder Endurance (Cayman) Ltd Svf sold 50,173 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $27.41, for a total value of $1,375,241.93. Following the sale, the insider now directly owns 21,566,288 shares of the company’s stock, valued at $591,131,954.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

  • On Monday, November 7th, Endurance (Cayman) Ltd Svf sold 132,978 shares of Vir Biotechnology stock. The shares were sold at an average price of $27.22, for a total value of $3,619,661.16.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $27.25 on Friday. The company has a market cap of $3.63 billion, a P/E ratio of 3.21 and a beta of -0.01. The stock has a 50 day simple moving average of $21.89 and a two-hundred day simple moving average of $24.34. Vir Biotechnology, Inc. has a fifty-two week low of $18.05 and a fifty-two week high of $58.00.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VIR. TheStreet raised Vir Biotechnology from a “d” rating to a “c-” rating in a research report on Monday, October 10th. SVB Leerink increased their price target on Vir Biotechnology from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Friday, November 4th. Barclays lowered their price objective on Vir Biotechnology to $67.00 in a research report on Monday, August 15th. Morgan Stanley increased their target price on Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a report on Friday, November 4th. Finally, Needham & Company LLC reduced their target price on Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $52.50.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Vir Biotechnology by 21.1% during the third quarter. Vanguard Group Inc. now owns 9,928,416 shares of the company’s stock valued at $191,420,000 after acquiring an additional 1,731,172 shares in the last quarter. State Street Corp increased its holdings in shares of Vir Biotechnology by 65.9% during the first quarter. State Street Corp now owns 4,193,764 shares of the company’s stock valued at $107,864,000 after acquiring an additional 1,665,657 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Vir Biotechnology by 8.3% during the third quarter. BlackRock Inc. now owns 13,873,726 shares of the company’s stock valued at $267,486,000 after acquiring an additional 1,062,036 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Vir Biotechnology by 168.9% during the third quarter. Renaissance Technologies LLC now owns 1,512,494 shares of the company’s stock valued at $29,161,000 after acquiring an additional 950,094 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Vir Biotechnology by 1,713.0% during the second quarter. Principal Financial Group Inc. now owns 471,935 shares of the company’s stock valued at $12,021,000 after acquiring an additional 445,904 shares in the last quarter. 64.55% of the stock is currently owned by institutional investors.

Vir Biotechnology Company Profile

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

See Also

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.